Areteia Therapeutics stock

Areteia Therapeutics Stock

HealthTech

Looking to sell Areteia Therapeutics stock or options?

Founded: 2022Funding to Date: $425Mhttps://areteiatx.com

Areteia Therapeutics is developing an oral medication aimed at treating eosinophilic asthma. Their platform concentrates on creating a drug that inhibits the maturation of eosinophils, potentially reducing inflammation and easing severe asthma symptoms. This approach could allow asthma patients to manage their condition more effectively, providing a more accessible option compared to injectable therapies.

Investors Include:

Viking Global Investors, Solas BioVentures, Maverick Capital, Saturn Partners, Bain Capital Life Sciences, Population Health Partners, GV, Marshall Wace, ARCH Venture Partners, Sanofi, Access Biotechnology.

Collective explained in 2 minutes

Learn how Collective's solutions enable you to manage your risk and maximize your wealth

Learn more